Literature DB >> 1749294

The fluoroquinolones.

R C Walker1, A J Wright.   

Abstract

The fluoroquinolone class of antibiotics promises to become as diverse and as important as beta-lactam agents. The fluoroquinolones inhibit bacterial DNA gyrase and are bactericidal. All fluoroquinolones have potent activity against most gram-negative bacteria; ciprofloxacin is the most active against Pseudomonas aeruginosa. Activity against gram-positive organisms is variable; methicillin-resistant Staphylococcus aureus has acquired resistance to the fluoroquinolones at an alarming rate. Currently available quinolones do not have, but new quinolone agents likely will have, substantial activity against anaerobic bacteria. Some quinolones are also active against Mycobacterium, Chlamydia, and Mycoplasma organisms. All fluoroquinolones have excellent absorption after oral administration; however, this process can be impaired by the presence of aluminum- or magnesium-containing antacids and by zinc, iron, or calcium supplements. Ciprofloxacin is also available for intravenous use. Although most fluoroquinolones do not achieve adequate cerebrospinal fluid levels, penetration into other tissues is excellent. Dosage adjustments for renal and hepatic dysfunction vary among the quinolones. Although side effects are rare, concomitant use of caffeine or theophylline with some quinolones may cause toxicity to the central nervous system. Because they may affect the development of cartilage, all fluoroquinolones are contraindicated in children, adolescents, and pregnant or breast-feeding women.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1749294     DOI: 10.1016/s0025-6196(12)62477-x

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  13 in total

1.  Activities of trovafloxacin, gatifloxacin, clinafloxacin, sparfloxacin, levofloxacin, and ciprofloxacin against penicillin-resistant Streptococcus pneumoniae in an in vitro infection model.

Authors:  E Hershberger; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

2.  Penetration of trovafloxacin into cerebrospinal fluid in humans following intravenous infusion of alatrofloxacin.

Authors:  N R Cutler; J Vincent; S S Jhee; R Teng; T Wardle; G Lucas; L C Dogolo; J J Sramek
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

3.  Machine learning on drug-specific data to predict small molecule teratogenicity.

Authors:  Anup P Challa; Andrew L Beam; Min Shen; Tyler Peryea; Robert R Lavieri; Ethan S Lippmann; David M Aronoff
Journal:  Reprod Toxicol       Date:  2020-05-16       Impact factor: 3.143

4.  Sparfloxacin-associated corneal epithelial toxicity.

Authors:  Aniruddha Kishandutt Agarwal; Jagat Ram; Ramandeep Singh
Journal:  BMJ Case Rep       Date:  2014-09-19

5.  Pharmacokinetic-pharmacodynamic modelling of the convulsant interaction between norfloxacin and biphenyl acetic acid in rats.

Authors:  S Marchand; C Pariat; S Bouquet; P Courtois; W Couet
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

6.  In vivo oral efficacy of levofloxacin for treatment of systemic Pseudomonas aeruginosa infections in a murine model of septicemia.

Authors:  S K Yagel; J F Barrett; D J Amaratunga; M B Frosco
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

7.  Canadian ciprofloxacin susceptibility study: comparative study from 15 medical centers. Canadian Ciprofloxacin Study Group.

Authors:  J M Blondeau; Y Yaschuk
Journal:  Antimicrob Agents Chemother       Date:  1996-07       Impact factor: 5.191

Review 8.  Treatment of Legionnaires' disease. Current recommendations.

Authors:  J Roig; A Carreres; C Domingo
Journal:  Drugs       Date:  1993-07       Impact factor: 9.546

Review 9.  Quinolone antibacterials. An update of their pharmacology and therapeutic use.

Authors:  N von Rosenstiel; D Adam
Journal:  Drugs       Date:  1994-06       Impact factor: 9.546

10.  Inhibitory Concentrations of Ciprofloxacin Induce an Adaptive Response Promoting the Intracellular Survival of Salmonella enterica Serovar Typhimurium.

Authors:  Sushmita Sridhar; Sally Forrest; Derek Pickard; Claire Cormie; Emily A Lees; Nicholas R Thomson; Gordon Dougan; Stephen Baker
Journal:  mBio       Date:  2021-06-22       Impact factor: 7.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.